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http://www.biomedcentral.com/1472-6750/14/24RESEARCH ARTICLE Open AccessSimultaneous multi-analyte urinary protein assay
for bladder cancer detection
Charles J Rosser1,2,3*, Yunfeng Dai4, Makito Miyake1, Ge Zhang1 and Steve Goodison1,2,5Abstract
Background: The ability to accurately measure multiple proteins simultaneously in a single assay has the potential
to markedly improve the efficiency of a myriad of clinical assays. Here, we tested the performance of a new,
multiplex protein array platform to quantitate three bladder cancer-associated proteins in urine samples. The
following analytes, interleukin 8 (IL8), matrix metallopeptidase 9 (MMP9), and vascular endothelial growth factor
A (VEGFA) were monitored using Q-plex, a customized multiplex ELISA system from Quansys Biosciences, and
individual target commercial ELISA kits. The performance of the two approaches was compared by evaluating
the diagnostic accuracy of the biomarker assays in samples from a cohort of 73 subjects of known bladder
cancer status.
Results: The combination biomarker panel analyses revealed an AUROC value of 0.9476 for the Q-plex assay, and
0.9119 for the combination of the single-target ELISA assays. The Q-plex assay achieved an overall diagnostic
sensitivity of 0.93 and specificity of 0.81, and the individual target ELISA assays achieved an overall sensitivity of
0.77 and specificity of 0.91.
Conclusion: Based on these encouraging preliminary data, we believe that the Q-Plex technology is a viable platform
that can be exploited as an efficient, highly accurate tool to quantitate multiplex panels of diagnostic proteins in
biologic specimens.
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While there continues to be an increasing number of
biomarker discovery studies published, very few new
cancer biomarkers have entered the clinic over the past
30 years. One reason for this has been the reliance on
assays of single biomarkers for the evaluation of cancers
that have a broad spectrum of molecular changes.
Coupled with the observed variation between individuals
and the heterogeneity within tumors, there has been a
necessary shift to molecular signatures comprised of
multiple biomarkers. Technologies that can efficiently,
simultaneously monitor molecular signatures would be
pivotal in moving promising biomarker panels towards
clinical utility. Quansys Biosciences have developed the
Q-Plex, a multiplex ELISA system that prints capture
antibodies as an array in a single well. In this study, we* Correspondence: crosser@cc.hawaii.edu
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unless otherwise stated.showed that this system could simultaneously and accur-
ately monitor three target proteins in urine samples.
Multiplexed ELISAs such as the Q-plex system can
maximize data generation from each sample, and pro-
vide a low cost per data point. The further optimization
and development of robust Q-plex assays in complex
biological fluids will allow this technology to become
more widely adopted.
Background
The advent of advanced molecular profiling techniques
has enabled the derivation of molecular signatures that
hold promise for more accurate, even individualized pa-
tient evaluation [1]. A number of molecular signature
assays are now being incorporated into clinical practice
[2,3], but the assays employed to monitor multiple tar-
gets per sample are, to date, rather complex and thus,
expensive, and often require centralized processing and
analysis. We have previously employed a range of prote-
omic [4,5] and genomic [6,7] technologies to profileLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Demographic and clinicopathologic
characteristics of 73 subjects comprising study cohort
Bladder cancer Benign controls
n = 31 n = 42
Median Age (range, y) 71 (54–93) 62 (24–81)
Male : Female ratio 26:5 35:7
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ing disease-associated biomarkers that could be devel-
oped for the non-invasive detection of bladder cancer.
The objective of the current feasibility study was to
test the ability of a customized multiplex assay system to
accurately and simultaneously monitor three urinary
protein biomarkers from one of our validated bladder
cancer signatures [8]. The levels of the three proteins,
interleukin 8 (IL8), matrix metallopeptidase 9 (MMP9),
and vascular endothelial growth factor A (VEGFA), were
quantitated in real-world urine samples and the diagnos-
tic performance of the multiplex system was compared
with analyses performed using three individual target
commercial ELISA kits.
The multiplex assay used Q-Plex™ technology (Quansys
BioScience, Logan, UT), which involves the micro-
spotting of individual groups of capture antibody in either
a cartesian or polar coordinate system on the bottom of a
96 well plate with each spot being its own ‘micro ELISA’
assay [9]. Micro-spotted systems have the advantage of
higher assay sensitivities and faster reaction kinetics due
to minimizing diffusion constraints for analyte/antibody
binding [10]. Standard ELISA incubation steps such as ini-
tial sample incubation, washing, secondary antibody incu-
bation, washing, incubation are employed, but the labeling
and reporting system used in the Q-Plex Array™ is chemi-
luminescent. Chemiluminescent ELISAs have been shown
to be more sensitive than colorimetric detection systems
[11,12].
In our study, the multiplex ELISA assay was shown to
be highly sensitive and to be consistently accurate across
wells and plates. Most importantly, the assay achieved
comparable diagnostic performance with respect to blad-
der cancer detection as the individual target commercial
ELISA assays [13-17]. The system can be applied to a
range of biological biomarker monitoring applications,
and we are working to expand the multiplex platform to
provide a high-throughput approach to quantitatively
detect more comprehensive bladder cancer-associated
diagnostic protein signatures in voided urine samples.
Results and discussion
Q-plex assay characterization
The physical components, a library of capture anti-
bodies, and the secondary reagents of the Q-Plex™
system have undergone extensive optimization for con-
sistent implementation [18,19]. Ranges for each analyte
assay were evaluated by dilution of standards to deter-
mine upper ranges where high-end hook effect and ap-
parent antibody saturation are avoided and lower ranges
that are above detection limits. Lower limits of detection
(LLD) were calculated based on 2× the standard devi-
ation of the background of 20 negative wells. LLD for
IL8, MMP9 and VEGFA were 0.4 pg/ml, 297 pg/ml and0.5 pg/ml, respectively, demonstrating sufficient sensitiv-
ity to detect proteins present in small amounts in voided
urine samples. The LLD data for the individual ELISA
kits (1.02 pg/ml for IL8, 66.1 pg/ml for MMP9, and
23.7 pg/ml for VEGFA) were comparable in range for
the most part. Any differences are presumably due to
the antigen binding characteristics of the proprietary
antibodies. Intra assay precision was measured with ac-
ceptance criteria of a coefficient of variation (%CV) of
less than 15.0. Median inter assay variability across all
plates was also determined to be less than 15% CV for
each analyte. As the technology is an array, all components
were checked for cross reactivity with other components in
the antigen and antibody cocktails and confirmed to have
less than 0.5% cross reactivity. Lower limits of quantifica-
tion (LLOQ) were determined to be the lowest point of
the 10-point positive standard curve where the back-fit re-
gression values were within 20% of the known value.
The minimal LLOQ, maximum and average LLOQ for
IL8, MMP9, and VEGFA were 0.3 pg/ml, 0.7 pg/ml, and
0.7 pg/ml; 35373 pg/ml, 52433 pg/ml, and 40782 pg/ml;
and 19 pg/ml, 613 pg/ml, and 419 pg/ml, respectively.
Only three of the 73 urine samples subsequently tested
(two for IL8 and one for VEGFA) fell outside the standard
curve and required extrapolation.
Urine sample analysis
After confirming the robustness of the multiplex assay
for these specific biomarkers, it was used to test a voided
urine sample set. Seventy-three clinical urine samples
from MD Anderson Cancer Center Orlando were made
available for analysis. Demographics and disease charac-
teristics of the entire cohort are summarized in Table 1.
The ability of each of the test biomarkers within the
multiplex array to predict the presence of bladder cancer
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cording to National Cancer Institute guidelines [20].
Urinary IL8 was the most accurate single biomarker for
bladder cancer detection with an AUROC of 0.907 (95%
CI: 0.830 - 0.985), a sensitivity of 90%, specificity of 86%,
PPV of 82% and NPV of 92%. Urinary MMP9 data gen-
erated an AUROC of 0.533 (95% CI: 0.392 - 0.674), sen-
sitivity of 45%, specificity of 76%, PPV of 58% and NPV
of 65%, and VEGFA as an individual analyte was noted
to have an AUROC of 0.524 (95% CI: 0.386 - 0.661), sen-
sitivity of 17%, specificity of 95%, PPV of 71% and NPV
of 61%. Through combinatorial analysis of all 3 bio-
markers using optimal cutoff values defined by Youden
index calculations, the AUROC (Figure 1) for the diag-
nostic panel using the multiplex array was 0.9476 [95%
CI: 0.903 - 0.992]. The combination assay achieved an
overall sensitivity of 0.93, specificity of 0.81, PPV of 0.78
and NPV of 0.94 for bladder cancer classification.
Spearman Correlation coefficient was not lower than
0.417 for any biomarker, thus comparison of the results
of the Q-Plex™ assay to those of the commercial ELISA
kits directed towards IL8, MMP9 and VEGFA were en-
couraging (Tables 2 & 3). The ability of each of the testFigure 1 Diagnostic performance of bladder cancer-associated
molecular panel comprised of three biomarkers. ROC curves
were plotted to illustrate the performance characteristics of the
3-biomarker signature for the detection of bladder cancer in urine
samples using the Q-Plex multiplex assay (solid line) and commercial
ELISA assays (dotted line). Based on the area under the ROC curve
(AUROC), Youden Index cutoff values that maximized the sum of
sensitivity and specificity were determined for the combination of
biomarkers. The Q-Plex multiplex assay achieved an overall sensitivity
of 0.93 and specificity of 0.81 (AUROC 0.9476). The combination of
data from the individual target ELISA assays achieved an overall
sensitivity of 0.77 and specificity of 0.91 (AUROC 0.9119). Thus, the
comparison of multiplex results with standard ELISA of these three
diagnostic biomarkers showed similar results and trends.biomarkers of the individual commercial ELISA assays
to predict the presence of bladder cancer was analyzed
using nonparametric ROC analyses. As with the multi-
plex assay, urinary IL8 was the most accurate single bio-
marker when monitored by individual ELISA with an
AUROC of 0.878 (95% CI: 0.783 - 0.972), a sensitivity of
87%, specificity of 86%, PPV of 82% and NPV of 90%.
Urinary MMP9 data generated an AUROC of 0.548
(95% CI: 0.409 - 0.688), sensitivity of 45%, specificity of
76%, PPV of 58% and NPV of 65%, while VEGFA was
noted to have an AUROC of 0.493 (95% CI: 0.356 -
0.630), sensitivity of 16%, specificity of 95%, PPV of 71%
and NPV of 61%. Through combination of data from all
3 biomarkers, the AUROC for the diagnostic panel from
the ELISA assays was 0.9119 [95% CI: 0.796 - 0.968],
with an overall sensitivity of 0.77, specificity of 0.91,
PPV of 0.86 and NPV of 0.84 for bladder cancer classifi-
cation. Thus, the comparison of multiplex results with
standard ELISA of these three diagnostic biomarkers
showed similar results and trends.
The Quansys Multiplex ELISA is now being optimized
to measure the remaining proteins of our highly accur-
ate bladder cancer-associated diagnostic panel com-
prised of 10 biomarkers [8]. We are currently producing
specific antibodies (Nonagen BioScience) for the 10 ana-
lytes in our diagnostic panel, which can potentially be
incorporated into a Quansys BioScience custom array
system for an integrated bladder cancer detection assay.
The ability to analyze multiple proteins per well, in
addition to dozens of samples per microplate, results in
marked improvements in efficiency and considerable
cost savings compared to single analyte ELISA.
Our study has several limitations. Notably, the study
cohort of 73 subjects was relatively small, and only
three targets from our validated 10-biomarker panel
were tested in this study. However this is a proof-of-
principle study in which we investigated the potential
for multiplexing analyte detection in real-world urine
samples. Lastly, as part of a biomarker discovery and
validation program, archived urines were retrieved from
tissue banks for analysis. Prolonged storage can result
in protein degradation and mute the performance of
diagnostic protein tests on such samples. Thus, valid-
ation of the performance of the multiplexed detection
of a bladder cancer biomarker panel in freshly voided
urines will be required.
There is growing demand to integrate multiplex
signatures to obtain favorable assay properties, such as
reduced sample volume, decreased processing time,
low cost analysis and low reagent consumption. Several
multiplex protein services are available (e.g., Sample
Testing Services of Quansys Biosciences Inc., microplate-
based; Aushon Biosystems, SearchLight Assays Services,
microplate-based; Milliplex MAP, bead-based; and RayBiotech,
Table 2 Comparison of Q-plex™ technology to traditional ELISA assays
Q-plex™ array Commercial ELISA assay
Cancer Benign Cancer Benign
IL8 (pg/ml)
Median 127.7 2.2 100.8 144.3
(Min, Max) (0.4, 5,087.5) (0.5, 185.3) (0, 4,355.3) (0, 506.3)
Mean ± SD* 423.6 ± 931.2 14.6 ± 40.9 276.8 ± 768.9 180.0 ± 138.2
MMP9 (pg/ml)
Median 268,688 248,730.5 2,833.2 545.3
(Min, Max) (176,103.9, 3,783,990.1) (162,655.6, 867,918.5) (0, 12,988.9) (0, 7,146)
Mean + SD 469,075.4 ± 655,960.4 320,746.6 ± 171,092.6 5,236.0 ± 4,144.5 876.5 ± 1,353.0
VEGFA (pg/ml)
Median 12,599.4 12,677.5 143.6 19.5
(Min, Max) (2,093.3, 498,114.9) (810.1, 262,356.7) (1.1, 9,874.1) (0, 184.2)
Mean + SD 33,483.5 ± 88,403.7 20,690.5 ± 39,702.7 1061.6 ± 2132.9 36.2 ± 47.4
*, p < 0.05 comparing cancer cohort to benign cohort for both Q-Plex™ Array and Commercial ELISA Assay.
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multiplex ELISA procedures appear suitable and reli-
able for tissue lysate and serum [21,22]. While there are
inherent, usually subtle differences between the various
multiplex technologies, the overall technique is rapid,
cost effective, and reliable. The reliability may be due
in part to specific capture and detection antibody pairs
that are optimized for the specific protein in question
without cross-reactivity. The Q-Plex system combines
powerful technology that allows the simultaneous de-
termination of the expression levels of many proteins
in biologic samples (e.g., urine, blood, sputum, cere-
brospinal fluid). The continued identification of bio-
marker proteins, which are associated with diagnosis
or prognosis, will result in this technology being more
widely adopted.
Conclusion
Based on these encouraging preliminary data, we believe
that the Q-Plex technology is a viable new platform thatTable 3 Performance comparison of Q-plex™ and individual-t
urine samples
Urinary analytes Assay platform AUROC [95% CI]
IL8 Q-Plex™ Array 0.907 [0.830 - 0.985]
Commercial ELISA 0.878 [0.783 - 0.972]
MMP9 Q-Plex™ Array 0.533 [0.392 - 0.674]
Commercial ELISA 0.548 [0.409 - 0.688]
VEGFA Q-Plex™ Array 0.524 [0.386 - 0.661]
Commercial ELISA 0.493 [0.356 - 0.630]
Combination Q-Plex™ Array 0.948 [0.903 - 0.992]
Commercial ELISA 0.912 [0.796 - 0.968]can be exploited to be a simple, yet accurate tool to
quantitate a panel of diagnostic proteins in biologic
specimens, in this case the detection of diagnostic blad-
der cancer biomarkers in voided urine samples. Import-
antly, this novel platform has acceptable inter assay
variability, as well as very sensitive levels of detection.
The platform can be readily implemented in a clinical la-
boratory and may be used as the basis for further work
by incorporation of our entire bladder cancer-associated
diagnostic signature.
Methods
Patients and specimen processing
Under MD Anderson Cancer Center Orlando Institu-
tional Review Board approval and informed consent,
prospectively collected voided urine samples (50 mL)
were assigned a unique identifying number before im-
mediate laboratory processing. Each urine sample was
centrifuged at 600 × g 4°C for 5 min. The supernatant
was decanted and aliquoted, and stored at -80°C in ourarget ELISA assays for the detection of bladder cancer in
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
90 86 82 92
87 86 82 90
45 76 58 65
45 76 58 65
17 95 71 61
16 95 71 61
93 81 78 94
77 91 86 84
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urinary tissue bank was queried for suitable samples to
analyze in the current study. Patients with known renal
disease or documented renal insufficiency were not se-
lected for inclusion in the current study. The study co-
hort consisted of 42 subjects with no previous history of
urothelia carcinoma, gross hematuria, active urinary
tract infection or urolithiasis (controls), and 31 subjects
with newly diagnosed urothelial carcinoma. All 73 sub-
jects a) had their urines analyzed by individual commer-
cial ELISA kits for IL8, MMP9 and VEGFA [8] and b)
had at least 5 mL of urine in the tissue bank for the current
analysis. Frozen supernatant aliquots from the 73 subjects
were shipped on dry ice to Quansys Bioscience, biotech-
nology company geared towards standardize or customize
singleplex and multiplex ELISA assays, for analysis.
Clinical information associated with these urine sam-
ples was collected. Data is reported using the STARD
criteria [23]. Aliquots of urine supernatants were thawed
and analyzed. The total protein concentration for each
sample was determined via absorbance at 280 nm
using a Nanodrop ND-1000 spectrophotometer (Thermo
Scientific, Wilmington DE), and creatinine assays were
performed on each sample for normalization with respect
to urine volume [17].
Q-plex multiplex assay
The Q-Plex technology is based on placement of immo-
bilized capture antibody in 350–500 μm spots at the bot-
tom of polypropylene 96-well plates to capture target
proteins (for further details see http://www.quansysbio.
com/assay-development/). Each spot is printed with a
different analyte capture antibody, in this case against
IL8, MMP9 and VEGFA. The sandwich immunoassay
complex that forms is labeled via biotin-streptavidin
with Horse Radish Peroxidase that generates light from
a chemiluminescent substrate. Two internal control as-
says are designed within the assay to ensure integrity of
results from each well through monitoring for the pres-
ence of interfering factors.
Thawed urine samples were handled on ice and di-
luted with Human Sample Dilution Buffer (Quansys),
designed to reduce effects from heterophilic antibodies
and other interferents [24]. Samples and standards
(50 μl) were loaded onto the Q-Plex™ plate with a multi-
channel pipettor in order to reduce pipetting error
and allowed to incubate for two hours. Laboratory
personnel were blinded to final diagnosis. Subsequently,
the sandwich immunoassay complex that forms was
incubated with biotin-streptavidin/Horse Radish Perox-
idase reagents for an additional two hours. Antigen stand-
ard curves were performed in duplicate diluting the
antigen standard 1:3 for 11 points with a single negative
point. Samples were diluted at ratios of 1 to 2 (sampleto buffer) (50%), 1 to 20 (5%) and 1 to 200 (0.5%). Each
dilution was loaded into three wells and measured in trip-
licate, a total of 9 wells per sample. Standard curves were
constructed using Q-View Software™, which allows for the
selection of multiple non-linear and linear equations to fit
the standard curve. Optimal curve fits were determined
by visual graph evaluation and comparison of Aikake’s in-
formation criteria (AIC) values [25]. A composite or
stacked image composed of individual exposures of 30, 60,
and 180 seconds with camera noise background subtrac-
tion was performed using Q-View Imager™. Levels of
chemiluminescent units, or pixel intensity units were mea-
sured by Q-View Software™. The range of pixel intensity
units is from 0 to 65536 (216 for a 16 bit image). Lower
limits of quantification (LLOQ) were determined to be the
lowest point of the 10-point positive standard curve where
the back-fit regression values were within 20% of the
known value.
Commercial Enzyme-Linked Immunosorbent Assays (ELISA)
The levels of human Interleukin 8 (IL8, Cat # ab46032
Abcam, Cambridge, MA, USA), Matrix Metalloprotein-
ase 9 (MMP9, Cat # DMP900 R&D Systems Inc., Minne-
apolis, MN, USA) and Vascular Endothelial Growth
Factor A (VEGFA, Cat # 100663 Abcam, Cambridge,
MA, USA) were monitored in voided urine samples, as
previously reported [8].
Data analysis
Nonparametric receiver operating characteristic (ROC)
curves in which the value for sensitivity is plotted
against false-positive rate (1-specificity) were generated
for association of biomarkers with disease status and
assay performance comparison. We defined a diagnostic
test as positive or negative for bladder cancer detection
by defining an optimal analyte concentration cutoff
value (Youden index), selected to maximize the sum of
the sensitivity and specificity [26,27]. Threshold cut-offs
used were: IL8, 83 pg/ml; MMP9, 365,525 pg/ml; and
VEGFA, 21,286 pg/ml. The relative ability of the com-
bination of biomarkers to indicate bladder cancer was
estimated by calculating the area under the ROC curves
(AUC), and the sensitivity and specificity was defined by
calculation of the Youden index. Statistical significance
in this study was set at p < 0.05 and all reported p values
were 2-sided. All analyses were performed using SAS
software version 9.3 (SAS Institute Inc., Cary, NC).
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